To cite this paper use one of the standards below:
As a part of Medicines for Malaria Venture’s efforts to deliver a clinical candidate that could be used as a Single Encounter Radical Cure and Prophylaxis (SERCaP) for Malaria, several compound libraries were screened against Plasmodium falciparum. The Screening Actives were prioritized based on their potency, physicochemical properties, and structural alerts. Then, top prioritized compounds were resynthesized or purchased to confirm the activity against P falciparum.
Once the activity of the Screening Actives is confirmed, the Hit Compounds are profiled in depth, to prioritize work on series that are more likely to progress to Lead Optimization Stage. For instance, throughout our work we found that besides testing the compounds against sensitive and resistant strains, we should also evaluate the propensity of generating resistance by determining the Minimum Inoculum for Resistance. Herein, we will present some of our progress towards the Validation of Hit Compounds.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper